SAVA

FILANA THERAPEUTICS INC

SAVA·14817C107·US·Common Stock·Healthcare - Biotechnology-13D/G

SAVA (FILANA THERAPEUTICS INC) is held by 58 institutional investors as of Q2 2026. Largest holders: VANGUARD CAPITAL MANAGEMENT LLC ($2.4M), TWO SIGMA INVESTMENTS, LP ($2M), MARSHALL WACE, LLP ($1.9M). Net institutional sentiment: Mixed.

58
Holders
(3 Elite)
$13.7M
Total Value
36% (64)
Consensus
23 buying - 41 selling
13F: Insider & Congress: Updated regularly
SAVA

Smart Money Verdict

View all
Loading verdict
Held by 58 funds
3 elite

Who's Trading

Source dates: Price Mar 3, 2026 · Insiders Nov 25, 2025 · Activists Jul 29, 2025 · Congress none

InsiderAJAnderson Robert Eugene JrBuy $25KNov 24, 2025
InsiderBRBarry RichardBuy $414KNov 20, 2025
InsiderBRBarry RichardBuy $202KNov 19, 2025
Checking access…

Top Holders

Checking access…
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
2M(+2.3%)$2.4M0.0%0.00%
27
Decreased
1.7M(-13.9%)$2M0.0%-22.34%
0
Decreased
1.6M(-20.6%)$1.9M0.0%-27.56%
0
Increased
1.5M(+2.8%)$1.7M0.0%-7.21%
18
Increased
668,792(+1518.4%)$795,8620.0%+0.47%
40
Increased
615,510(+3.2%)$732,7360.0%-88.02%
17
Decreased
485,025(-13.3%)$577,1800.0%+7.74%
0
Increased
389,601(+19.2%)$463,6250.0%0.00%
28
New
318,380$378,8720.0%0.00%
33
Increased
315,889(+15.3%)$375,9080.0%0.00%
27
Decreased
292,017(-34.7%)$347,5010.0%-22.02%
0
Decreased
244,008(-19.4%)$290,3700.0%+20.98%
0
Decreased
209,105(-12.9%)$248,8350.0%-88.61%
0
Decreased
132,597(-0.1%)$157,7900.0%0.00%
0
Decreased
132,298(-3.4%)$157,4350.0%+6.71%
0
Increased
119,952(+4.2%)$142,7430.0%+8.01%
23
Decreased
114,322(-23.4%)$136,0430.0%-87.85%
0
Decreased
99,879(-28.7%)$118,8560.0%-25.14%
0
New
75,000$89,2500.0%0.00%
30
Increased
64,614(+94.0%)$76,8910.0%-11.00%
34

Showing 1-20 of 70

1 / 4
SAVASAVAFILANA THERAPEUTICS INC

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used